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Alterations of B cell subpopulations have been described up to date as characterizing advanced stage of HIV-1 infection. However,
whether such defects are relevant in subjects with a preserved number of CD4+ Tc e l l s( >350 cells/μL) is unclear. In a cross-
sectional study, we investigated if signs of B cells exhaustion and impaired viral immune surveillance are present in a cohort of 43
asymptomatic HIV-1-infected patients with preserved CD4+ T cell counts (>350 cells/μL) and highly active antiretroviral therapy
(HAART) untreated. A dramatic expansion of exhausted tissue-like memory B cells (CD10
−CD21lowCD27−)w a so b s e rv e d .Bc e l l s
alteration was related to an increase in Torque teno virus (TTV) load, used as surrogate marker of immune function. Successfully
HAART-treated patients showed normalization of B cell subpopulations frequency and TTV load. These results provide new
insights on B cell in HIV-1 infection and show that development of B cell abnormalities precedes CD4+ T cell decline.
1.Introduction
Through direct or indirect eﬀects, HIV-1 infection leads
to several perturbations on most cells of the immune
system. The persistent viral replication induces loss of
CD4+ T cells and a general chronic cellular activation
that aﬀect viability, subsets distribution, phenotype, and
function of all the major immune cell populations [1]. B
cells exhibit numerous eﬀects of HIV-1-induced immune
activation. Increased expression of activation and prolif-
eration markers, polyclonal B cell hyperactivation, and
hypergammaglobulinemia are some of the B cell defects
detectable in HIV-1-infected patients [2, 3]. Moreover,
B cells derived from HIV-1-infected patients show sev-
eral alterations in vitro, as high spontaneous antibod-
ies secretion, defective responses to B cell stimuli, and
impaired costimulatory functions [4–8]. These functional
defects have been recently linked to perturbation in the
frequency of several B cell subpopulations. Na¨ ıve B cells
(CD21highCD27−) constitute the largest B cell population
in the blood of healthy individuals, followed by memory B
cells (CD21highCD27+). The frequency of memory B cells is
strongly decreased in HIV-1-infected individuals, and this
occurrence is accompanied by an increased levels of na¨ ıve
B cells, activated mature B cells (CD20+CD21lowCD27+),
and plasma cells (CD20−CD21lowCD27+)[ 9–11]. Moreover,
a relevant expansion of B cell subpopulations characterized
by a CD21lowCD27− phenotype has been recently described
in chronically infected patients in advanced stage of HIV-
1 infection with a pronounced CD4+ T cell lymphopenia
and ongoing HIV-1 replication [12]. This B cell population,
which is normally present at low frequency in the peripheral
blood of healthy individuals, can be further divided, depend-
ing on the expression of CD10, into immature/transitional
B cells (CD10+) or exhausted tissue-like memory B cells
(CD10−)[ 13–15].2 Clinical and Developmental Immunology
Torque teno virus (TTV) is a single-strand DNA virus
harmlessly carried by the majority of healthy individu-
als [16]. TTV is considered a surrogate marker of the
immunological status of the host [17]. In fact, TTV viral
load has been found signiﬁcantly higher in HIV-1-infected
patientspresentingAIDSanddecreasedsurvivalthanhealthy
individuals [18].
Here we demonstrate that asymptomatic patients na¨ ıve
for HAART with preserved CD4+ Tc e l lc o u n t s( >350
cells/μL) show an aberrant B cell subsets distribution and a
concurrent increase in TTV viral load compared to HIV-1-
uninfected individuals as well as HAART successfully treated
patients.
2.MaterialsandMethods
2.1. Study Population. Blood samples were obtained from
a cohort of 43 chronic HIV-1-infected patients na¨ ıve for
HAART and without any history of opportunistic infections
or malignancies. Clinical features of these patients are
described in Table 1. Blood samples were also obtained from
a cohort of 20 HAART-treated patients, aviremic for at
least 12 months (Table 2), and from 34 healthy laboratory
workers. The HIV-1-infected patients enrolled in this study
were recruited at the Institute of Infectious and Tropical
Diseases of the University of Brescia, provided their written
informed consent. The study was approved by the Ethical
Committee of the University Hospital of Brescia according
to the declaration of Helsinki.
2.2. FACS Analysis. Blood samples were analyzed for 3-
or 4-colors surface staining after lysis of red blood cells
(FACS Lysing Solution, BD Bioscences, Milan, Italy). Mon-
oclonal antibodies directly conjugated either to ﬂuorescein-
isothiocyanate (FITC), or phycoerythrin (PE), or peridinin-
chlorophyll-protein (PerCP), or AlloPhycocyAnin (APC)
speciﬁc for CD10, CD19, CD21, CD27, CD3, CD4, CD8,
and CD127 were used (BD Bioscences). Flow cytometric
analysis was performed using FACSCalibur ﬂow cytometer
(BD Biosciences), and 50.000 events (gated on lymphocytes)
were acquired. Data were analyzed by CellQuest software.
2.3. IL-7 Serum Levels Detection. Detection of IL-7 serum
concentration was performed through Quantikine HS IL-
7 Immunoassay, according to the protocol provided by the
supplier (R&D Systems, Minneapolis, USA).
2.4. Virus Detection and Quantiﬁcation. HIV-1 plasma viral
load was detected using Roche Amplicor PCR kit (Roche-
Diagnostic, Milan, Italy). DNA extracted from 200μLo f
plasma samples was examined for TTV genome using
a single step universal TaqMan real-time PCR assay as
previously described [17]. The sensitivity of the assay was of
3.0log10 DNA copies/mL of plasma. All samples were tested
simultaneously in triplicate.
2.5. Statistical Analysis. Statistical analysis were performed
usingGraphPadPrismv4.0cforMacOSX.Thedistributions
of each immune parameter between healthy donors and
HIV-1-infected patient cohorts were compared using the
nonparametric Mann-Whitney U test. All P values were 2
sided and unadjusted. Correlation between variables was
tested using Spearman’s rank correlation coeﬃcient test. For
all statistical analysis, the 0.05 level of signiﬁcance was used
(P<0.05). Data in the text were expressed as median.
3. Results
3.1. Several B Cell Subset Alterations in Asymptomatic and
HAART-Na¨ ıve HIV-1-Infected Patients. In the present study
we examined the frequency and the function of B cell
populations in 43 HIV-1-infected patients characterized by
being clinically asymptomatic, with CD4+ Tc e l lc o u n t>350
cell/μL(median:510cell/μL),medianviralloadof6779RNA
copies/mL and HAART-na¨ ıve. As control, B cell populations
were examined in 34 healthy individuals.
We observed that the median of CD19+ Bc e l lc o u n t so f
the asymptomatic HIV-1-infected patients was superimpos-
able to the median of healthy individuals (129.5 versus 143
cell/μL, resp.) (Figure 1(a)). Moreover, the frequency of B
cell subsets, such as mature/activated, immature/transitional
or tissue-like memory, resting/memory, and na¨ ıve B cells
was analyzed in all tested individuals. Although the normal
number of total B cells, several perturbations were detected
in the B cell subpopulations of asymptomatic HIV-1-
infected patients. As shown in Figures 1(b) and 1(c) among
the CD21high B cells we observed that the frequencies of
both resting/memory (CD27+), and na¨ ıve (CD27−)w e r e
signiﬁcantly lower in the peripheral blood of the asymp-
tomatic HIV-1-infected patients compared to healthy donors
(median percentage: 23.5 versus 29.4, P = 0.026, and 54.2
versus 64.4, P<0,005, resp.). However, we observed that
activated/mature CD21lowCD27+ and immature/transitional
or tissue-like memory CD21lowCD27− B cells were signiﬁ-
cantly higher in the asymptomatic HIV-1-infected patients
compared to uninfected donors (median percentage: 9.6
versus 2.4, P<0.0001, and 10.4 versus 2.1, P<0.0001,
resp.). A previous study from Malaspina et al. [13] showed
that the frequency of CD21lowCD27− B cells was increased in
HIV-1-infectedpatientsinadvancedstageofdisease(CD4+T
cell count <200 cell/μL). This cell subset included both
CD10+elements, accounting for an immature/transitional B
cell phenotype, and CD10− cells deﬁning exhausted tissue-
like memory B cells. In our cohort of asymptomatic HIV-
1-infected patients the percentage of CD10+ B cells was
particularly low and similar to those of healthy donors. The
CD21lowCD27− B cells subtype was essentially negative for
CD10, attesting for an exhausted tissue-like memory B cells
phenotype (Figure 1(b)). The percentage of CD21lowCD27−
B cells positively correlated to the HIV-1 viral load (r =
0.39, P = 0.012). A higher percentage of CD21lowCD27−
B cells was detected in patients with high plasma viremia
(>10000RNAcopies/mL),and,viceversa,alowerpercentage
of circulating CD21lowCD27− B cells was found in patients
with low plasma viremia (<10000 RNA copies/mL) (P<
0.01) (Figure 2). No correlation was observed between theClinical and Developmental Immunology 3
Table 1: Proﬁles of asymptomatic HIV-1-infected patients.
Patients Sex Age (years) HIV-1 risk group CDC stage HIV-1 viral load (RNA copies/mL) CD4 T cell count (cell/μL)
1 M 49 Heterosex A1 6342 500
2 F 33 Heterosex A2 760 471
3M 3 0 H e t e r o s e x A 1 <50∗ 650
4 F 40 Heterosex A1 9893 470
5 F 21 Heterosex A1 160116 786
6 F 72 Heterosex A1 2940 536
7 M 55 Homosex/bisex A1 76871 477
8 M 27 Heterosex A1 39880 540
9 F 44 Heterosex A1 9337 487
10 F 42 Heterosex A1 74 857
11 F 48 Heterosex B1 62078 505
12 M 48 Unknown A1 6778 384
13 M 28 Unknown A1 58322 622
14 M 26 Homosex/bisex A1 274979 550
15 F 36 Drugs user B1 1332 454
16 M 43 Homosex/bisex A2 27684 356
17 F 43 Heterosex A1 1201 417
18 M 30 Drugs user A1 15756 523
19 M 33 Heterosex A1 789 742
20 M 42 Hematic product contact A1 107 570
21 M 47 Drugs user A1 323 552
22 M 47 Drugs user A1 <50 684
23 M 50 Heterosex A1 55681 510
24 M 55 Heterosex A2 67431 481
25 M 45 Heterosex A1 14781 386
26 F 46 Heterosex A1 143 494
27 F 54 Heterosex A1 276 417
28 M 32 Homosex/bisex A1 11091 685
29 M 28 Heterosex A1 362 620
30 M 34 Heterosex A1 16841 668
31 F 48 Drugs user A1 <50 640
32 M 44 Drugs user A1 <50 2049
33 F 24 Drugs user A2 49716 469
34 M 49 Homosex/bisex A2 3569 489
35 F 28 Heterosex A1 6390 555
36 M 49 Heterosex A1 487 834
37 M 39 Heterosex A1 32750 523
38 M 35 Homosex/bisex A2 1121 408
39 M 49 Homosex/bisex A1 13057 496
40 M 39 Homosex/bisex A2 40811 478
41 M 40 Homosex/bisex A2 1713 474
42 M 43 Homosex/bisex A2 29763 355
43 M 43 Homosex/bisex A1 62035 574
∗<50 HIV-1 RNA copies/mL: undetectable levels.
percentage of CD21lowCD27− B cells and CD4+ Tc e l lc o u n t
(r =− 0.27, P = 0.085, not shown).
3.2. Increased Levels of IL-7 in Sera of Asymptomatic HIV-1-
Infected Patients. IL-7 is a pleiotropic cytokine controlling
T lymphopoiesis and T cell peripheral expansion through
interaction with its surface receptor (IL-7Rα or CD127)
[19]. Several investigators observed increased serum levels
of IL-7 in HIV-1-infected patients characterized by severe
CD4+ lymphopenia, and showed direct correlation between
IL-7 serum concentration and viral load, loss of CD4+ T
cells, and alteration of B cell subsets [13, 20]. Moreover, the4 Clinical and Developmental Immunology
Table 2: Proﬁles of HAART-treated HIV-1-infected patients.
Donors Sex Age
(years)
HIV-1 risk group HIV-1 viral load CD4 T cell count
(cell/μL)
CDC before
therapy
Nadir Therapy
1M 44 Drug user <50 481 A3 93 EFV+FTC+TDF
2M 43 Drug user <50 662 A2 201 NVP+3TC+TDF
3F 34 Heterosex <50 1124 A2 308 NVP+AZT+3TC
4M 36 Homosex/bisex <50 1031 C3 9 NVP+FTC+TDF
5M 46 Drug user <50 740 C3 43 AZT/r+FTC+TDF
6M 60 Heterosex <50 512 C3 39 AZT+3TC+ABC
7M 48 Heterosex <50 731 A2 208 NVP+3TC+ABC
8M 53 Heterosex <50 566 A3 94 EFV+FTC+TDF
9M 44 Drug user <50 527 C2 274 AZT/r+3TC+TDF
10 F 41 Heterosex <50 636 A2 311 EFV+3TC+ABC
11 M 56 Homosex/bisex <50 638 C3 84 AZT/r+3TC+ABC
12 M 40 Drug user <50 823 A2 365 AZT+3TC+ABC
13 M 49 Heterosex <50 754 A3 23 AZT+3TC+ABC
14 F 31 Drug user <50 633 A2 280 FSP/r+3TC+ABC
15 F 49 Drug user <50 846 B3 57 NVP+FTC+TDF
16 M 39 Homosex/bisex <50 701 A2 332 AZT/r+FTC+TDF
17 F 43 Heterosex <50 1067 A2 339 EFV+FTC+TDF
18 F 40 Drug user <50 524 B3 166 NVP+3TC+ABC
19 M 44 Homosex/bisex <50 701 A2 239 NVP+FTC+TDF
20 M 44 Heterosex <50 564 C3 23 LPV/r+FTC+TDF
<50 HIV-1 RNA copies/mL: undetectable table.
frequency of immature/transitional CD10+CD21lowCD27−
B cells is positively correlated to the IL-7 concentration
detected in lymphopenic HIV-1-infected patients [13]. For
these reasons, high levels of IL-7 are considered a hallmark
of advanced HIV-1 disease. However, we observed a dra-
matic increase of IL-7 serum levels also in asymptomatic
HIV-1-infected patients compared to healthy individuals
(median concentration: 12.9pg/mL versus 1.7pg/mL, P<
0.01) despite a relatively preserved number of CD4+ T
cells (median number count: 510 versus 831 cell/μL)
(Figure 3(a)). No correlation between IL-7 serum levels and
CD4+ T cell counts or exhausted tissue-like memory B cell
subset frequency were detected (Figure 3(b)).
3.3. Increase of TTV Load in Asymptomatic HIV-1-Infected
Patients and Correlation with the CD21lowCD27− BC e l l s
Frequency. Sofar,ourﬁndingsshowedprofoundphenotypic
alterations in the B cell compartment of patients in the
asymptomatic stage of HIV-1 infection. Previous studies
showed that B cell subsets, abnormally expressed in the
peripheral blood of HIV-1-infected patients in advanced
stages of disease, and scarcely detectable in healthy individ-
uals, displayed several functional defects [13, 21]. The aim
of our study was trying to understand the impact of these
uncommon B cell subsets on immunological surveillance in
vivo.
TTV is an ubiquitous virus which infects up to 80% of
the healthy population [22], and that is present at high titer
inthebloodofpatientsinadvancedstagesofHIV-1infection
compared to healthy subjects. In HIV-1-infected patients
TTV load inversely correlated with the CD4+ Tc e l lc o u n t
[18]. TTV plasma viremia was measured in all individuals
enrolledinourstudy.AsymptomaticHIV-1-infectedpatients
showed a signiﬁcantly higher amount of circulating TTV
compared to healthy individuals (titer median: 5.7 versus 4.6
log DNA copies/mL, P<0.005, Table 3). A direct correlation
wasobservedbetweenTTVloadandbothHIV-1viremiaand
percentage of CD21lowCD27− Bl y m p h o c y t e s( r = 0.49 P<
0.01, and r = 0.40, P<0.01, resp.) (Figure 4). These
data suggest that in asymptomatic HIV-1-infected patients
the increased percentage of CD21lowCD27− B cells may be
related to the lack of in vivo immunological control of TTV
replication.
3.4.NormalBCellSubsetsFrequencyandNormalTTVPlasma
Levels in HAART-Treated Patients. We then investigated the
eﬀect of HAART on the B cell compartment of a cohort
of HIV-1-infected individuals who experienced low levels of
CD4+ T cell counts during the course of infection (median
nadir: 183 cell/μL),and maintained undetectable HIV-1 viral
load for the last 12 months of therapy. At the time of our
study, all patients belonging to this cohort displayed CD4+
T cell counts higher than asymptomatic therapy-na¨ ıve HIV-
1-infected patients (median 682 cells/μL versus 510 cell/μL,
P<0.0001). The absolute number of B cells was signiﬁcantly
higher in HAART-treated patients as compared to both
asymptomatic HIV-1-infected HAART-na¨ ıve patients and
healthy individuals (median: 233 cell/μL versus 129.5 cell/μL,Clinical and Developmental Immunology 5
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Figure 1: Peripheral blood B cell subsets alterations in asymptomatic HIV-1-infected patients. (a) Comparative analysis of CD19+ Bc e l l
counts (cell number/μL) in HIV-1-uninfected individuals and asymptomatic HIV-1-infected patients. (b) Analysis of CD21 and CD27
expression on B cells from HIV-1-uninfected individuals and asymptomatic HIV-1-infected patients, and analysis of CD10 expression on
CD21low/CD27− B cells. Percentages of B cell subsets were determined by four-color ﬂow cytometry analysis of CD19, CD21, CD27, and
CD10 surface expression molecules. Proﬁles of expression of CD21 and CD27 are shown for one representative of each group. Cells were
gated according to the lymphocytes forward and side scatter pattern and the CD19+ cells. (c) Comparative analysis of B cell subpopulations
in HIV-1-uninfected individuals and asymptomatic HIV-1-infected patients. Frequency of CD21highCD27− na¨ ıve B cells (upper left panel),
CD21highCD27+ resting memory B cells (upper right panel), CD10−CD21lowCD27− exhausted tissue-like memory B cells (lower left panel),
andCD21lowCD27+ mature/activatedBcells(lowerrightpanel)areshownforthetotalofdonors.Diﬀerencesbetweengroupswereevaluated
using the two-tailed Mann-Whitney U test, and were considered signiﬁcant at P<0.05. Into the box plots, horizontal lines represent median
values for each group, boxes show the 25th and 75th percentiles, and bars show SD. N.S. = not signiﬁcant.6 Clinical and Developmental Immunology
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Figure 2: Association between exhausted tissue-like memory B cells and HIV plasma viremia. Correlation between CD10−CD21lowCD27−
B cell percentages and HIV-1 plasma viremia (RNA copies/mL) in asymptomatic HIV-1-infected patients (a). Comparative analysis
of CD10−CD21lowCD27− B cell percentages in asymptomatic patients with HIV-1 plasma viremia ≤ to 10000RNA copies/mL and
asymptomatic patients with HIV-1 plasma viremia > to 10000RNA copies/mL (b). Association of 2 diﬀerent data groups were analyzed
by Spearman’s rank test; P and rho values are indicated. Each symbol represents one individual, and regression line is shown. Diﬀerences
between groups were evaluated using the two-tailed Mann-Whitney U test, and were considered signiﬁcant at P<0.05. Into the box plots,
horizontal lines represent median values for each group, boxes show the 25th and 75th percentiles, and bars show SD.
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Figure 3: IL-7 serum levels in asymptomatic HIV-1-infected patients and correlation with CD10−CD21lowCD27−B cells frequency. (a)
Comparative analysis of IL-7 serum levels (pg/mL) in HIV-1-uninfected donors and asymptomatic HIV-1-infected patients. ELISA was
performed to measure the IL-7 concentration. (b) Correlation between IL-7 serum levels and percentage of CD10−CD21lowCD27− Bc e l l s
in asymptomatic HIV-1-infected patients. Diﬀerences between groups were evaluated using the two tailed Mann-Whitney U test, and were
considered signiﬁcant at P<0.05. Into the box plots, horizontal lines represent median values for each group, boxes show the 25th and 75th
percentiles, and bars show SD. Association of 2 diﬀerent data groups were analyzed by Spearman’s rank test. Each symbol represents one
individual, and regression line is shown. N.C.= no correlation.
P<0.005, and versus 143 cell/μL, P<0.01, resp.)
(Table 3). In the cohort of HAART-treated patients we
observed no presence of uncommon B cell populations with
percentages of CD21lowCD27− and of CD21lowCD27+ Bc e l l s
superimposable to those of healthy individuals (Figure 5).
At the same time, the percentage of CD21highCD27− Bc e l l
subpopulation was higher in HAART-treated than asymp-
tomatic HIV-1-infected cohort patients (P<0.0005), and
the IL-7 levels of treated-patients were superimposable to
those of healthy donors. Finally, a successful immunological
surveillance was observed in HAART-treated patients as they
displayed a TTV plasma viremia within ranges commonly
observed in healthy subjects (median: 4.1 versus 4.6log DNA
copies/mL).Clinical and Developmental Immunology 7
Table 3: Eﬀects of HAART on B cells frequency, IL-7 serum levels, and TTV viral load.
Healthy Asymptomatic
HIV-1 infected HAART treated
P (HAART
treated versus
healthy)
P (HAART treated
versus asymptomatic
HIV-1 infected)
CD19+ B cell count
(cell/μL)
143.0 129.5 232.5 <0.01 <0.005
CD21−CD27− Bc e l l
frequency (%)
2.1 10.4 2.7 NS <0.0001
CD21−CD27+ Bc e l l
frequency (%)
2.4 9.6 1.7 NS <0.0001
CD21+CD27+ Bc e l l
frequency (%)
29.4 23.5 22.4 <0.05 NS
CD21+CD27− Bc e l l
frequency (%)
64.4 54.2 73.0 NS <0.0005
IL-7 serum level
(pg/mL)
1.7 12.9 2.0 NS <0.01
TTV plasma viremia
(log DNA copies/mL)
4.6 5.7 4.1 NS <0.001
NS: not signiﬁcant.
Results are expressed as median.
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Figure 4: Perturbation in TTV immune surveillance in asymptomatic HIV-1-infected patients. (a) Correlation between TTV and HIV-
1 viral loads (log DNA copies/mL, and log RNA copies/mL, resp.) in plasma derived from asymptomatic HIV-1-infected patients. TTV
and HIV viral loads were measured by PCR and RT-PCR, respectively. (b) Correlation between plasma TTV titer and percentage of
CD10−CD21lowCD27− B cells in asymptomatic HIV-1-infected patients. Association of 2 diﬀerent data groups were analyzed by Spearman’s
rank test; P and rho values are indicated. Each symbol represents one individual, and regression line is shown.
4. Discussion
Disturbances in diﬀerentiation and function of B cells
characterize HIV-1 infection, and mostly, these impairments
are correlated to the loss of CD4+ T cells and the increase of
HIV-1 load [12]. In the present study, we demonstrate that
asymptomatic HIV-1-infected patients na¨ ıve for HAART
are characterized by normal B cell numbers but impaired
B cell subsets frequencies. In particular, we observed that
CD21lowCD27− and CD21lowCD27+ B cells were overex-
pressed, whereas the frequencies of CD21highCD27− and
CD21highCD27+ B cells, which respectively account for na¨ ıve
and resting memory B cells, were lower compared to healthy
donors. The increased uncommon CD21lowCD27− Bc e l l
population in the asymptomatic HIV-1-infected patients
consisted exclusively of exhausted tissue-like memory B cells
since no CD10 molecule surface was detected in this cellular
subset. It is likely that the appearance of CD21lowCD27+
B cells, which have undergone HIV-1-induced activation
and diﬀerentiation to plasma blasts, and are usually referred
as activated mature elements, as well as the appearance of
CD21lowCD27− B cells, which derive from exhausted B cell
subpopulation, can be ascribed to the B cell hyperactivation
driven by the chronic yet asymptomatic presence of HIV-18 Clinical and Developmental Immunology
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and side scatter pattern and the CD19+ cells (upper panel).
in patients. The presence of exhausted B cells in asymp-
tomatic patients is strongly correlated to the HIV-1 load
but not to the CD4+ T cell counts. Immature/transitional
CD10+CD21lowCD27− B cells, previously described in the
peripheral blood of HIV-1 positive patients in advanced
stages of disease, were not present in the cohort of asymp-
tomatic patients probably because they appear consequently
to a strong reduction of CD4+ Tc e l lc o u n t s[ 13, 15]. In fact,
immature/transitional B cells were also observed in patients
with non-HIV-1-related idiopathic CD4+ lymphopenia sug-
gesting that HIV-1-induced CD4+ lymphopenia (and not
HIV-1 viremia itself) drives the expansion of these elements
in HIV-1-infected patients [23]. Therefore, our data show
that exhausted tissue-like memory B cells emerge indepen-
dently from immature/transitional B cells in HIV-1-infected
patients, and precede the appearance of the latter possibly
arisingfromhomeostaticpressuresinducedbylymphopenia,
and/or from conditions that increase the expression levels of
early B cell stimulatory factors such as IL-7 [13, 23].
Several studies report that CD4+ lymphopenia driven
by HIV-1 infection or bone marrow transplantation and
idiopathic CD4+ T lymphopenia are often associated with
increasedserumlevelsofIL-7[21,23–25].Inordertoexplain
the increased levels of IL-7 in CD4+ T lymphopenic indi-
viduals, it has been suggested that IL-7 augmentation occurs
as part of a compensatory eﬀect to enhance diﬀerentiation,
survival, and expansion of T cells in order to respond to
the HIV-1-mediated T cell depletion [24]. Surprisingly, we
detected increased levels of IL-7 in sera of asymptomatic
HIV-1-infected patients, but no correlations with CD4+ T
cells count or HIV-1 load were detected. This result may ﬁnd
a possible explanation in the recent discovery by Guimond
et al. [26] that systemic IL-7 concentrations increase solely
because of diminished use of the lymphokine by target cells.
So, it is possible to hypothesize that the presence of
exhausted memory B cells in asymptomatic HIV-1-infected
patients is likely to prejudice the proper functioning of
immunecells,and,therefore,asuitableimmunesurveillance.
So far, no pathological eﬀect can be ascribable to
TTV [22, 27]. TTV viral load seems to depend on the
immunological status of the host, being patients with
tumours or HIV-1 infection characterized by a higher TTV
load compared to healthy individuals [16, 28]. Moreover,
recent ﬁndings obtained by studying TTV in bone marrow
transplanted patients show that the increase of viral loads
is correlated with an increase in the percentages of dys-
functional CD8+CD57+ T lymphocytes circulating in blood
[17, 29]. In the study we show that asymptomatic HIV-1-
infected individuals have TTV viral load higher than healthy
controls and that its titre is directly correlated to the HIV-
1 viral load but not to the CD4+ T cells count. Moreover,
TTV viral load directly correlated to the percentage of
CD21lowCD27− B cells. These correlations may attest for a
scarce immune control of TTV replication by B cells and for
an already compromised immune surveillance in untreated
asymptomatic HIV-1-infected patients.
Several studies have shown that HAART-mediated sup-
pression of HIV-1 plasma viremia is followed by nor-
malization of B cell counts and hyperactivation. In addi-
tion, reduction of HIV-1 viremia by HAART is associated
with decreased frequency of exhausted tissue-like memoryClinical and Developmental Immunology 9
Bcells[30].Herewehavedescribedthatpatientswhoexperi-
enced HAART, leading to an undetectable HIV-1 viremia for
the last 12 months of therapy, display a normal B cell subsets
distribution. The role of HAART in the normalization
of IL-7 serum levels is controversial: some investigators
showed only a partial decrease in the IL-7 levels, never
declining toward normal values whereas others documented
a complete normalization of this immunological parameter
[19, 31]. In our study, successfully HAART-treated patients
showed IL-7 values superimposable to those of healthy HIV-
1-uninfected individuals.
Interestingly, we reported that all HAART-treated pa-
tients experienced TTV load to levels usually detected in
healthy individuals. This ﬁnding shows that antiretroviral
therapies aimed at controlling HIV-1 load and normal-
izing B cell subpopulations can help to recover immune
functions to levels capable of controlling the replication of
this endogenous virus. Normalization of B cell counts and
subpopulations by HAART is followed by improved B cell
responses to both T cell-independent and T cell-dependent
immunogens [29, 32–34]. Of particular interest is the recent
observation that an early control of viral replication through
HAART preserves the longevity of B cell responses in
vaccinated HIV-1-infected children thus underscoring the
direct role of HIV-1 viremia in B cell terminal diﬀerentiation
[35]. These observations have important implications not
only for preserving immune responses against secondary
pathogens but also for maintaining or boosting HIV-1
speciﬁc immune responses, including antibody responses.
5. Conclusions
We have provided evidences that asymptomatic HIV-1-
infected patients with a preserved CD4+ Tc e l ln u m b e r ,
and na¨ ıve for HAART, display alterations in B cell subset
phenotype and impaired immune responses, as manifested
by their inability to control TTV replication. On the other
hand, normal B cell phenotypes and counts were found in
patients who initiated HAART during chronic disease and
displayed a negative HIV-1 viral load in the last 12 months
of therapy. Normal B cell subpopulations in HAART-treated
patients were mirrored by a normal TTV viral load, attesting
for a recovery of adequate immunological surveillance. From
this point of view, HAART as well as therapies aimed at
decreasing immune cell deregulation can help to better
control the loss of immune function if administered earlier
during HIV-1 infection.
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